NASDAQ · TLSA
Healthcare · Biotechnology
$0.96
Down-$0.00 (-0.41%)
Updated Sep 13, 2026, 5:47 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TLSA closed at $0.96 after 19 trading sessions, down 16.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.978 | $0.996 | $0.9343 | $0.96 | 277.71K |
| Sep 10, 2026 | $0.9599 | $0.9797 | $0.95 | $0.964 | 194.82K |
| Sep 9, 2026 | $0.9904 | $1.0108 | $0.953 | $0.9767 | 245.62K |
| Sep 8, 2026 | $1.02 | $1.03 | $0.9601 | $0.9897 | 908.22K |
| Sep 4, 2026 | $0.972 | $1.06 | $0.9507 | $1.02 | 573.92K |
| Sep 3, 2026 | $1.05 | $1.05 | $0.95 | $0.9745 | 517.94K |
| Sep 2, 2026 | $0.9622 | $0.998 | $0.91 | $0.9315 | 488.44K |
| Sep 1, 2026 | $0.9923 | $0.9998 | $0.91 | $0.9636 | 515.08K |
| Aug 31, 2026 | $1.02 | $1.045 | $0.9703 | $0.988 | 429.93K |
| Aug 28, 2026 | $1.10 | $1.10 | $0.998 | $1.01 | 566.42K |
| Aug 27, 2026 | $1.09 | $1.14 | $1.05 | $1.08 | 272.31K |
| Aug 26, 2026 | $1.12 | $1.126 | $1.0771 | $1.09 | 402.73K |
| Aug 25, 2026 | $1.18 | $1.18 | $1.10 | $1.11 | 441.01K |
| Aug 24, 2026 | $1.14 | $1.25 | $1.135 | $1.15 | 959.02K |
| Aug 21, 2026 | $1.12 | $1.17 | $1.09 | $1.14 | 832.75K |
| Aug 20, 2026 | $1.08 | $1.16 | $1.0402 | $1.12 | 1.57M |
| Aug 19, 2026 | $1.12 | $1.1672 | $1.02 | $1.07 | 2.09M |
| Aug 18, 2026 | $1.14 | $1.18 | $1.06 | $1.12 | 1.62M |
| Aug 17, 2026 | $1.15 | $1.17 | $1.05 | $1.15 | 1.92M |
The latest Smart Investors Daily articles mentioning TLSA.
TLSA research
Company profile and research snapshot.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | BTIG | Buy | — |
| Jun 13, 2022 | ThinkEquity | Buy | — |
| Apr 12, 2021 | Zacks Investment Research | Not Rated | — |
| Sep 21, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing...
Benzinga · Sep 3, 2026
Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
Benzinga · Sep 3, 2026
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
Yahoo · Aug 24, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TLSA.
No results
No recent SID articles mention TLSA.
